Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02647905 · ClinicalTrials.gov registry record · NA
Evaluation of the Accuracy of an Implanted Glucose Sensor
A NA study, sponsored by Senseonics.
- Completed
- Registry status
- NA
- Development phase
- 90
- Enrollment target
NCT02647905: Completed NA study, sponsored by Senseonics.
NCT02647905 is a NA study that has completed, run by Senseonics. The registered enrollment target is 90 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02647905, a NA study, has completed, sponsored by Senseonics.
- COMPLETED
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of this clinical investigation is to evaluate the accuracy of the Senseonics Continuous Glucose Monitoring System (Senseonics CGM System) measurements when compared with reference standard measurements The investigation will also evaluate safety of the Senseonics CGM System usage.
Primary Outcome
Mean absolute relative difference (MARD) for paired Sensor and reference measurements through 90 days post-insertion for reference glucose values from 40-400 mg/dL will be calculated for comparison.
Interventions
- DEVICE Continuous Glucose Monitoring System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2016-01 |
| Est. Completion | 2016-07 |
| Phase | NA |
What the finished NCT02647905 record still lists
NCT02647905 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Continuous Glucose Monitoring System is the first listed.
NCT02647905 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02647905 about?
NCT02647905 is a clinical study titled "Evaluation of the Accuracy of an Implanted Glucose Sensor". The purpose of this clinical investigation is to evaluate the accuracy of the Senseonics Continuous Glucose Monitoring System (Senseonics CGM System) measurements when compared with reference standard measurements The investigation will also evaluate safety of the Senseonics CGM System usage.
What is the current status of trial NCT02647905?
This trial is currently completed. It is a NA study. The enrollment target is 90 participants. The study started on 2016-01. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02647905?
The interventions under investigation include: Continuous Glucose Monitoring System (DEVICE).
Who is sponsoring clinical trial NCT02647905?
This trial is sponsored by Senseonics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02647905's enrollment target sits among peer trials
90 941st of 2000 higher than 1,029 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia